New evidence from The Lancet: COLLISION and COVER-ALL redefine IR standards

We're excited to share a major breakthrough for interventional radiology, thanks to two clinical studies – COLLISION and COVER-ALL – published in The Lancet earlier this year.

The COVER-ALL trial (https://www.sciencedirect.com/science/article/abs/pii/S246812532500024X) unequivocally shows that relying on visual assessment for thermal ablation is insufficient. The study demonstrates that software-based assessment nearly triples the minimal ablative margin (2.2 mm to 5.9 mm) and leads to a significant drop in local tumor progression at 2 years (16% to 5%), with no severe adverse events. This underscores the critical need for objective verification. Our Ablation-fit technology directly addresses this, ensuring precise, standardized, and effective ablation assessment.

Published in The Lancet Oncology, the COLLISION trial (https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00660-0/abstract) is a game-changer for interventional oncology. It establishes thermal ablation as a safe and effective alternative to surgery for small colorectal liver metastases. Key findings include comparable overall survival and unexpectedly similar local recurrence rates, with better local control for ablation. This evidence is set to influence future guidelines, making ablation a standard treatment option. Our technologies, like Endosight and Ablation-fit, are designed to accelerate mastery of these procedures, making advanced ablation more accessible and consistent.

These landmark studies from The Lancet aren't just data; they are a clear indication of the future of interventional radiology. We're proud to develop the innovative medical devices that empower clinicians to deliver the highest standard of care, ensuring precision, consistency, and improved outcomes for patients.